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Abstract
 
Recent data using MHC/peptide tetramers and dimers suggests that the T cell coreceptors,
CD4 and CD8, although important for T cell activation, do not play a direct role in facilitating
T cell receptor (TCR) binding to multivalent MHC/peptide ligands. Instead, a current model
proposes that coreceptors are recruited only after a stable TCR–MHC/peptide complex has al-
ready formed and signaled. In contrast, we show using multimeric class I MHC/peptide ligands
that CD8 plays a critical (in some cases obligatory) role in antigen-specific TCR binding. T cell
activation, measured by calcium mobilization, was induced by multimeric but not monomeric
ligands and also showed CD8 dependency. Our analysis using anti-CD8 antibodies revealed that
binding to different epitopes of CD8 can either block or augment TCR–MHC/peptide inter-
action. These effects on TCR binding to high-affinity agonist ligands were even more pro-
nounced when binding to multimeric low-affinity ligands, including TCR antagonists, was
studied. Our data have important implications for the role of CD8 in TCR binding to MHC/
peptide ligands and in T cell activation. In addition, our results argue against the view that mul-
timeric MHC/peptide ligands bind directly and solely to the TCR; rather, our data highlight a
pivotal contribution of CD8 for this association.
Key words: MHC/peptide tetramers • T cell activation • cytotoxic T lymphocyte • calcium • 
ﬂow cytometry
 
Introduction
 
The T cell coreceptors CD4 and CD8 are known to bind
class II and class I molecules directly and to be critical for
development and activation of most T cells (1–3). How-
ever, the function of these molecules in TCR binding to
MHC/peptide ligands is unclear. A key role would be an-
ticipated, as coengagement of the TCR and coreceptor
greatly enhance T cell responses (1, 4), and direct participa-
tion of the CD8 coreceptor in TCR–MHC/peptide ligand
interactions has been suggested (5). However, these studies
did not determine if the coreceptor functions to facilitate
TCR engagement with ligand, enhance signal transduc-
tion, or both. Indeed, the model in which CD4 and CD8
assist in forming the TCR–MHC/peptide interaction has
been repeatedly challenged. Xu and Littman suggested that
efficient CD4 coreceptor function required binding of as-
sociated Lck with previously assembled TCR–MHC/pep-
tide complexes after TCR activation (6). A similar role has
been proposed for CD8 based on analogous data (7). Re-
cent studies using multivalent peptide/class II MHC ligands
have allowed more direct measurement of MHC/peptide
binding to the TCR. These reports all reached the same,
surprising conclusion: CD4 plays no role in forming a sta-
ble TCR interaction with multimeric ligands (8–10). Pre-
vious work showed that CD4 is important in interactions
with agonist but not antagonist MHC/peptide ligands,
concluding that a stable TCR interaction induced by ago-
nist ligands was a prerequisite for recruitment of the core-
ceptor rather than the other way around (11, 12).
Less had been reported on the role of CD8 in TCR–
MHC/peptide binding. Yet recent work using surface plas-
mon resonance assays failed to detect any enhancement by
CD8 of TCR binding to specific class I MHC/peptide
ligands (13). Furthermore, CD8 binding to class I MHC
molecules is known to be enhanced by activation of tyro-
sine kinases through the TCR (7, 14, 15). These data have
lead to the conclusion that CD8, like CD4, might partici-
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pate in T cell responses only after the TCR has already sta-
bly bound and been activated by its ligand (7, 13). Finally,
several groups have reported analysis of specific T cell pop-
ulations using MHC/peptide multimers in the presence of
anti-CD8 antibodies (16–19). This shows that multimer
binding can occur in the presence of anti-CD8 antibody,
although, importantly, the effect of antibody on CD8 func-
tion was not determined. Thus, a composite model from
these studies is that both CD4 and CD8 are recruited into
the TCR–peptide/MHC complex only after it has stably
assembled and had an opportunity to participate in signal
transduction (6–11, 13, 20–22).
Recent studies on the role of coreceptors in T cell acti-
vation, however, suggest that there may be key differences
between the functional role of CD4 and CD8. Using solu-
ble class I MHC/peptide complexes, it was shown that cal-
cium mobilization could be induced by monomeric class I/
peptide complexes, providing that CD8 was available (23).
In the absence of CD8, dimeric MHC/peptide ligand was
necessary and sufficient to induce such activation (24). A
different pattern emerged from analysis of TCR–class II
MHC interactions. Boniface et al. showed that CD4 was
critical for very early activation events (the acidification re-
sponse) induced by MHC/peptide multimers but that even
high concentrations of MHC/peptide multimers were un-
able to induce a sustained calcium flux response (10). Fur-
thermore, even in the presence of CD4, MHC/peptide
monomers failed to induce any class II–restricted T cell re-
sponse (10). These data further support the model in which
CD4 has a critical role for class II–restricted T cell activa-
tion and mediates this effect after TCR encounter with
multimeric MHC/peptide ligand. But the data from Delon
et al. suggests that CD8 may play a different role, potentiat-
ing the response to rare and/or low-affinity ligands (23). It
is difficult to compare these systems, however, as the ap-
proach used by Delon et al. did not determine if CD8 fa-
cilitated binding of the MHC/peptide complex to the
TCR or whether the effect of CD8 could be attributed
purely to enhanced signal transduction.
To address these issues, we studied the role of CD8 in
TCR binding and activation using soluble multimeric
MHC/peptide ligands. In contrast to the models discussed
above, we demonstrate here that CD8 is critical in class I/
peptide multimer binding to TCR in two well defined,
class I–restricted TCR-transgenic systems. Indeed, in one
of these systems (OT-I), the coreceptor was not only in-
volved in but absolutely required for significant TCR
binding to multimeric MHC/peptide ligands. Further-
more, we found that class I multimers, but not monomers,
were capable of inducing rapid calcium mobilization and that
this response is dependent on CD8 in both TCR-trans-
genic systems studied. Finally, we showed that different an-
tibodies against CD8 had dramatically different results on
multimer binding and T cell activation. Specifically, although
most anti-CD8 antibodies blocked multimer binding to the
T cell, one antibody enhanced specific multimer binding.
This enhancement was especially dramatic in the case of
multimers containing low-affinity TCR ligands, including
TCR antagonists. Thus, our data is in contrast with that of
other groups, who propose that TCR binding to antagonist
ligands is coreceptor independent.
 
Materials and Methods
 
Mice and Cells.
 
6–12-wk-old OT-I, OT-I recombination ac-
tivating gene (RAG)-1
 
2
 
/
 
2
 
,
 
1
 
 and 2C mice were generated and
maintained under specific pathogen–free conditions. Major lymph
nodes were harvested, and a single-cell suspension was generated
as previously described (25). The majority of LN cells in OT-I
RAG-1
 
2
 
/
 
2
 
 mice are CD8
 
1
 
OT-I TCR
 
1
 
, and these cells were
used without further purification. For most staining experiments
and all activation experiments involving normal OT-I and 2C
mice, the cells were passed over a “CD8 Cellect” column (Cy-
tovax), which removes B cells and CD4 cells, thus enriching the
population for CD8
 
1
 
 and/or CD4
 
2
 
8
 
2
 
 T cells.
 
Peptides and MHC Multimers.
 
The peptides OVAp (SIINFEKL),
SIYp (SIYRYYGL), G4 (SIIGFEKL), and E1 (EIINFEKL) have
been described previously (26–28) and were synthesized by Re-
search Genetics.
Production of K
 
b
 
/
 
b
 
2m (microglobulin)/peptide multimers fol-
lowed standard protocols (16, 18). Plasmids encoding K
 
b
 
 molecules
with the BirA recognition sequence at the COOH terminus and
human 
 
b
 
2m molecules (gifts of J. Altman, Emory University, At-
lanta, GA and E. Pamer, Yale University, New Haven, CT, re-
spectively) were transformed and overexpressed in 
 
Escherichia coli
 
.
The synthesized proteins were purified from inclusion bodies, de-
natured, and mixed with the appropriate K
 
b
 
 binding peptide, and
the mixture was allowed to renature in suitable oxidoreductive
conditions over 48 h. After biotinylation using BirA (Avidity), the
monomeric MHC/peptide complexes were purified via fast pro-
tein liquid chromatography (FPLC) on a Superdex 200 column
(Pharmacia Biotech, Inc.). The efficiency of biotinylation was as-
sessed by sequential immunoprecipitation with avidin-conjugated
beads (Pierce Chemical Co.), followed by anti-K
 
b
 
 antibody (Y3)-
conjugated CNBr Sepharose beads (Sigma Chemical Co.), and
was routinely estimated to be 
 
.
 
80% efficient using this method.
After concentration of the appropriate-sized fractions, the bio-
tinylated K
 
b
 
/peptide complexes were mixed with streptavidin
(SA)–PE (Molecular Probes, Inc.) or SA–allophycocyanin (Phar-
Mingen) at a 4:1 molar ratio. Multimers which eluted in the pre-
dicted range of tetramers were purified via a second round of
FPLC size exclusion. However, in some experiments the unpuri-
fied multimer preparation was used for staining with no significant
difference in staining profiles. Multimers were tested over a range
of doses for flow cytometry and were typically used at 10 
 
m
 
g/ml.
 
Antibodies and Flow Cytometry.
 
T cells (5 
 
3
 
 10
 
5
 
) were stained
in 50 
 
m
 
l of FACS buffer (PBS, 1% FCS, and 3 mM azide) or RP-
10 with 3 mM azide at the temperatures and times indicated in
the figures. Typically, MHC multimers (10 
 
m
 
g/ml) and anti-CD8
antibodies (50 
 
m
 
g/ml unless stated otherwise) were added simul-
taneously. In Fig. 4, OT-I T cells were stained with OVA/K
 
b
 
multimers for 2 h at 4
 
8
 
C, washed twice, and reincubated with
FACS buffer alone or with saturating concentrations of anti-CD8
FITC-conjugated antibodies. The following anti-CD8
 
a
 
 antibod-
ies were used: 3.168 (rat IgM; reference 29), 53.6.7 (rat IgG2a;
references 30 and 31) (PharMingen), and CT-CD8a (rat IgG2a;
Caltag Labs.). The anti-CD8
 
b
 
 antibody used was 53.5.8 (rat
 
1
 
Abbreviations used in this paper:
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IgG1; references 30 and 31; PharMingen). Cells were analyzed
using a Becton Dickinson FACSCalibur™. For Ca
 
2
 
1
 
 flux mea-
surements, the T cells were loaded with Indo-1AM at 37
 
8
 
C as
described previously (32), washed, and then incubated on ice
with or without FITC-conjugated anti-CD8 antibodies for 30–
60 min. After short centrifugation, the cells were resuspended
into media at 37
 
8
 
C and analyzed immediately on a FACSVan-
tage™ instrument. After establishing a baseline for 1 min, mono-
meric or multimeric MHC/peptide complexes (to 10 
 
m
 
g/ml) or
free OVAp (to 200 nM) was added. As the molecular mass of
OVA/K
 
b
 
–SA–PE multimers is 
 
z
 
400 kD, 10 
 
m
 
g/ml represents a
molar concentration of 
 
z
 
25 nM for the multimer and 100 nM
for the OVAp molecules within the multimer. Thus, the concen-
tration of free OVAp added in these experiments was double that
of OVAp included in the multimer. The cells were quickly mixed
and then analyzed by flow cytometry for an additional 7–15 min,
as indicated. Data were analyzed using both CELLQuest™ (Bec-
ton Dickinson) and FlowJo (TreeStar) software.
 
Results
 
We sought to determine if CD8 participates in binding
of multivalent MHC/peptide ligands to class I–restricted
TCRs. OT-I and 2C are TCR-transgenic mouse strains that
bear receptors specific for the mouse class I molecule K
 
b
 
complexed with OVAp and SIY, respectively (26–28). Us-
ing standard procedures, K
 
b
 
/peptide multimeric complexes
were synthesized bearing each of these peptides (16, 18). As
direct CD8 binding to K
 
b
 
 molecules has been reported
(33), it was important to determine if interaction of these
multimers with CD8 T cells was dependent on the speci-
ficity of the TCR. Fresh T cells were isolated from the
lymph nodes of OT-I and 2C transgenic mice and stained
with MHC/peptide multimers for 1 h at 37
 
8
 
C in tissue cul-
ture media containing azide to block T cell activation (con-
ditions derived from Crawford et al. [9]). These binding as-
says revealed fine TCR specificity in multimer binding,
such that the 2C T cells bound the K
 
b
 
/SIY multimer but
not the OVA/K
 
b
 
 multimer, whereas the reciprocal pattern
of binding was observed for OT-I cells (Fig. 1 A). This
correlates with reports of functional assays using these same
receptors and ligands (25). Double staining under the same
conditions with the anti-CD8
 
a
 
 antibody 53.6.7 revealed
that specific multimer staining was preserved in the pres-
ence of this antibody. It is important for subsequent exper-
iments to note that there is a population of TCR express-
ing CD8
 
2
 
 T cells in 2C animals (Fig. 1 B). These cells are
known to express the clonotypic TCR at levels similar to
the CD8
 
1
 
 2C cells (34–36; our data not shown). Both
CD8
 
1
 
 and CD8
 
2
 
 2C cells stain with the K
 
b
 
/SIY multimer,
although staining intensities differ for these two popula-
tions (Fig. 1 B).
We next tested a panel of antibodies that recognize dis-
tinct epitopes on the CD8
 
a 
 
and -
 
b 
 
chains to determine their
effects on the TCR–MHC/peptide interaction. In stark con-
trast to the results using the 53.6.7 antibody, we found that
saturating concentrations of two anti-CD8
 
a
 
 antibodies,
3.168 (Fig. 2 A) and CT-CD8a (data not shown), and the
anti-CD8
 
b
 
 antibody 53.5.8 (data not shown), showed al-
most total blockade of K
 
b
 
/OVA multimer binding to OT-I
cells (Fig. 2 A and data not shown). Furthermore, we noted
that 53.6.7 actually enhanced binding over that of the multi-
mer without anti-CD8 (Fig. 2 A). To further quantitate the
role of CD8 in multimer binding, a titration of the anti-CD8
antibodies was performed. The enhancing effect of 53.6.7
and blocking by the other CD8 antibodies was titratable and
covered a similar dose range (Fig. 2 B). Importantly, no
staining of OT-I cells with the noncognate K
 
b
 
/SIY multi-
mer was observed, regardless of the anti-CD8 antibody used
(Fig. 2, A and B). This indicates that the anti-CD8 antibod-
ies did not change the fine specificity of multimer binding.
Also, these results were not influenced by the dose of multi-
mer used, as similar enhancement or blockade was observed
using higher or lower doses of the OVA/K
 
b
 
 multimer (data
not shown). Furthermore, similar profiles of enhancement or
blockade were observed using unconjugated or allophycocy-
anin-conjugated anti-CD8 antibodies, arguing against some
artifact of FACS compensation (data not shown).
Figure 1. Binding of MHC/peptide multimers is dependent on the
specificity of the TCR. (A) Lymph node cells from 2C and OT-I mice
were depleted of B cells and CD41 cells and stained for 1 h at 378C with
the indicated PE-conjugated multimers (Mult.). The mean fluorescence
intensity (MFI) of 2C cells was 401 when stained with the SIY/Kb multi-
mer versus 4 using the OVA/Kb multimer. MFI for OT-I cells was 5 for
the SIY/Kb multimer and 326 with the OVA/ Kb multimer. (B) Staining
as in A, except these cells were stained with the anti-CD8a antibody
53.6.7 in addition to the indicated multimer. Numbers represent the per-
centages of cells in respective quadrants. 
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We considered that staining the cells at 37
 
8
 
C could allow
effects such as CD8 and/or TCR capping and internaliza-
tion to occur. Furthermore, it is known that even high
concentrations of azide do not prevent ligand-triggered TCR
internalization at 37
 
8
 
C (37, 38, and our unpublished obser-
vations). To control for these phenomena, we compared
staining performed entirely at 4
 
8
 
C in the presence of 3 mM
azide. These conditions prevent antibody-induced internal-
ization and TCR downregulation (37, 38, and our unpub-
lished observations). As shown in Fig. 3, multimer binding
was slightly improved with staining at 37 versus 4
 
8
 
C, as ex-
pected from Crawford et al. (9). However, the effects of
the anti-CD8 antibodies were identical under both condi-
tions: the antibody 53.6.7 slightly enhanced multimer bind-
ing (Fig. 3), whereas antibodies 3.168 (Fig. 3), CT-CD8a,
and 53.5.8 (not shown) all blocked multimer binding com-
pletely at both temperatures. Similar results were obtained
when the cells were stained for longer times at these tem-
peratures (data not shown). These data indicate that the
CD8 effects observed are not dependent on T cell activa-
tion or TCR/CD8 internalization. However, given the
potential complications of TCR and/or CD8 internaliza-
tion and signaling at higher temperatures, subsequent stain-
ing was performed at 4
 
8
 
C in the presence of 3 mM azide.
Using this system, we could also study the dynamic na-
ture of MHC/peptide multimer binding. As we know that
the half-life of the OT-I TCR–OVA/K
 
b
 
 complex is rela-
tively short, (39) the binding of individual “heads” of the
OVA/K
 
b
 
 multimer to the TCR is expected to be dynamic
rather than static, such that each head of the multimer dis-
sociates and reassociates with TCRs over time. If CD8 was
involved in this process, then anti-CD8 antibodies might
affect the stability of prebound MHC multimers. To test this,
we compared the effects of anti-CD8 antibodies on multi-
mer binding to OT-I cells under two conditions: (a) when
 
antibodies and OVA/K
 
b
 
 multimers were added simulta-
neously (Fig. 4 A) or (b) when OVA/K
 
b
 
 multimers were
allowed to bind first and the cells were subsequently incu-
bated with anti-CD8 antibodies (Fig. 4 B). In the absence
of anti-CD8 antibodies at either step, multimer staining ap-
pears quite stable, decreasing only slightly in the second in-
cubation (compare Fig. 4, A and B). As expected, multimer
staining was greatly decreased when the blocking anti-CD8
antibodies (3.168 or CT-CD8a) were added during multi-
mer binding (Fig. 4 A), but there was also significant loss of
multimer when these antibodies were added only in the sec-
ond incubation (Fig. 4 B). This displacement effect could be
observed kinetically, in that multimer binding was not re-
duced to the same extent after only 45 min (rather than 2 h)
of incubation with the blocking anti-CD8 antibodies (data
not shown). It is also important to note that the blockade
of multimer binding was more efficient when multimer
and anti-CD8 antibodies were added simultaneously rather
than sequentially (compare Fig. 4, A and B). In contrast to
Figure 2. Variable effect of
CD8 antibodies on MHC class I
multimer binding OT-I LN T
cells. LN cells from an OT-I
RAG-12/2 animal were stained
with the indicated PE-conju-
gated multimer (Mult.) at 378C
for 2 h, with or without simulta-
neous staining with saturating
amounts of the indicated FITC-
conjugated anti-CD8 antibodies.
(A) Cells were stained with
OVA/Kb multimer (top) or SIY/
Kb multimer (bottom), with no
anti-CD8 antibody (open histo-
gram), 53.6.7 (dotted histogram),
or 3.168 (filled histogram). The
effect of the antibodies CT-CD8a or 53.5.8 was similar to that of 3.168 for both multimers, and data using these antibodies is omitted for clarity.
(B) The MFI of staining with the indicated multimer in the presence of titrated anti-CD8 antibodies.
Figure 3. Effects of temperature on multimer staining and effects of
anti-CD8 antibodies. OT-I RAG-12/2 LN cells were stained at 48C (1 h,
left panels) or 378C (1 h, right panels) with the SIY/Kb multimer (shaded)
or OVA/Kb multimer (open) without anti-CD8 antibody (A) or with
CD8 antibody 53.6.7 (B) or 3.168 (C). The block with 3.168 causes the
OVA/Kb multimer to overlap the histogram for the negative control,
SIY/Kb multimer. 
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these results, the “enhancing” anti-CD8 antibody (53.6.7)
did not cause loss of prebound multimer but, on the con-
trary, appeared to stabilize multimer staining at the level
observed at the beginning of the second incubation (com-
pare Fig. 4, A and B). Together, these data support the
model of a dynamic nature of multimer binding to the
TCR and suggest that CD8 participates in both the initial
association of the TCR with MHC/peptide multimer and
the stability of this interaction.
As mentioned previously, 2C TCR–transgenic mice are
interesting in that they develop a natural population of T
cells that are positive for the 2C TCR yet are CD8
 
2
 
 (34).
Such T cells are functional, as they can respond to TCR
ligand, albeit only at high doses (35, 36). These results sug-
gest that 2C cells may be relatively coreceptor independent,
and hence we were interested in what role CD8 might play
in multimer binding to the 2C receptor. All 2C cells stained
specifically with the K
 
b
 
/SIY multimer in the absence of
anti-CD8 antibody, but the profile was bi-modal, with a
multimer
 
high
 
 and a multimer
 
low
 
 population (Fig. 5 A). The
percentages of multimer
 
low
 
 and multimer
 
high
 
 populations
correlate with the percentage of CD8
 
2
 
 and CD8
 
1
 
 cells, re-
spectively (data not shown), suggesting that CD8 plays a
role in multimer binding to the 2C. We confirmed a role
for CD8 using anti-CD8 antibodies. Staining with 3.168,
CT-CD8a, or 53.5.8 caused disappearance of the K
 
b
 
/SIY
multimer
 
high
 
 population, this group of cells becoming mul-
timer
 
low
 
. In contrast, 53.6.7 did not cause this change in
multimer staining (Fig. 5 A) and, in some experiments,
slightly increased the staining on the K
 
b
 
/SIY multimer
 
high
 
population. As in the case of OT-I cells, the staining using
nonspecific multimer was not significantly affected by use
of any anti-CD8 antibody (Fig. 5 B).
More directly, we analyzed K
 
b
 
/SIY multimer binding on
both the 2C CD8
 
1
 
 and CD8
 
2
 
 populations, identified using
 
either 53.6.7 or 3.168 (Fig. 5, C–J). Multimer binding to
the CD8
 
1
 
 population was higher than to the CD8
 
2
 
 popu-
lation when 53.6.7 was used to reveal CD8, whereas CD8
 
1
 
T cells stained with 3.168-bound multimer no better than
CD8
 
2
 
 2C cells (Fig. 5, C–J). In this experiment, there was
a slight enhancement of SIY/K
 
b
 
 multimer staining of the
CD8
 
1
 
 population when 53.6.7 was used (compare Fig. 5,
C and D). These results are thus analogous to the influence
of anti-CD8 antibodies on OT-I TCR binding, with the
main difference between the systems being the degree of
multimer binding in the absence/blockade of CD8: negli-
gible in the case of the OT-I receptor, but merely reduced
in the case of multimer binding to 2C TCR.
Reports from Madrenas et al. and Hampl et al. indicate
that TCR binding to TCR antagonist ligands is coreceptor
(CD4) independent (11, 12). To characterize the role of CD8
in binding TCR antagonists in our system, we used K
 
b
 
/pep-
tide multimers containing altered peptide ligands with
known affinity for the OT-I TCR. The variant peptide G4
Figure 4. CD8 effect on multimer dissociation. (A) OVA/Kb multimers
were allowed to bind to OT-I RAG2/2 cells for 2 h at 48C in the presence
or absence of the anti-CD8 antibodies, as indicated. (B) In the same experi-
ment, OT-I cells that were stained with OVA/Kb multimers in the absence
of anti-CD8 antibody as in A were washed twice and then incubated for an
additional 2 h at 48C with or without anti-CD8 antibodies as indicated.
Figure 5. Role of CD8 in multimer binding to 2C cells. 2C LN cells
were depleted of B cells/CD41 T cells and stained for 2 h at 48C with
PE-conjugated SIY/Kb multimer (A) or OVA/Kb multimer (B), with no
anti-CD8 antibody (open histogram), 53.6.7 (dotted histogram), or 3.168
(filled histogram). The effect of the antibodies CT-CD8a or 53.5.8 was
similar to that of 3.168 for both multimers, and data using these antibod-
ies is omitted for clarity. In a separate experiment, SIY/Kb multimer
staining of 2C T cells was determined in the absence (C) or presence of
the anti CD8 antibodies 53.6 (D) or 3.168 (E). F, G, and H show CD8/
FITC staining for the cells in C, D, and E, respectively. The multimer
staining of gated CD82 (shaded) and CD81 (open) populations revealed
with 53.6.7 (I) or 3.168 (J) is also shown.340 Role of CD8 in TCR Binding to MHC/Peptide Multimers
is a weak agonist/antagonist for OT-I, whereas E1 is an an-
tagonist (26, 32, 40). The OT-I affinity for these ligands is
known and matches their biological function, with the rank
order of affinity being OVA.G4.E1 (reference 39 and
Alam, S.M., and N.R.J. Gascoigne, personal communica-
tion). Staining OT-I cells with these Kb/peptide multimeric
complexes revealed that the order of affinity matches the
intensity of staining, such that multimer complexes con-
taining OVA stained more intensely than those containing
G4 and the E1 multimer stained only slightly (but repro-
ducibly) above the negative control level (Fig. 6). That the
rank order of staining mirrors TCR affinity is consistent
with data from Crawford et al. (9). We next tested the ef-
fect of anti-CD8 antibodies on binding of these multimers.
Once again, the “blocking” anti-CD8 antibodies 3.168
(Fig. 6), CT-CD8a, and 53.5.8 (not shown) totally negated
binding of all multimeric ligands. In contrast, the enhanc-
ing effect of 53.6.7 was observed for all of the specific OT-I
ligands and was extremely marked for the low-affinity ligand
E1/Kb, bringing staining with this multimer well above the
level of the control (SIY/Kb; Fig. 6). These data demonstrate
that binding of multimers containing low-affinity MHC/
peptide ligands is still strongly influenced by CD8 participa-
tion. Furthermore, these data indicate that use of the “en-
hancing” 53.6.7 antibody can significantly augment staining
of a multimer containing an antagonist ligand (E1/Kb).
Data from Delon et al. (23) indicated that monomeric
MHC/peptide ligands could stimulate a Ca21 flux provided
that CD8 was available, whereas data from Boniface et al.
(10) indicated that even multimeric MHC class II/peptide
ligands fail to induce a sustained Ca21 response. Hence, it
was possible that our experiments using multimer staining
would not be predictive of the capacity of these ligands to
activate CD8 T cells. We thus wished to explore the capac-
ity of our class I MHC/peptide monomers and multimers
to stimulate naive T cells and study the role of CD8 in such
stimulation.
As an early activation event that can easily be studied in
real time, we focused on induction of Ca21 mobilization
measured by flow cytometry. Use of fluorochrome-labeled
multimers allowed us to study multimer binding in real
time and correlate this with Ca21 mobilization. As shown in
Fig. 7, OT-I T cells bound specific multimers rapidly
(within seconds), and this slightly preceded the initiation of
a Ca21 flux response. The vast majority of OT-I T cells (82–
91% over three experiments) participated in robust Ca21
mobilization under these conditions, and the level of intra-
cellular Ca21 did not return to baseline over the time
course studied. These data therefore indicate that the Ca21
flux response induced by cognate MHC/peptide multimers
is synchronous and sustained. In contrast to these results,
nonspecific multimers neither bound nor induced Ca21 mo-
bilization (Fig. 7), and neither did the OT-I TCR antago-
nist E1/Kb multimer (data not shown).
Because the OT-I T cells themselves express Kb, it was
possible that OVA peptide was released from the multim-
eric complexes and presented via T cell–T cell interactions.
As a control for this, we added double the concentration of
free OVA peptide used in the multimer sample. This re-
sulted in no Ca21 mobilization (Fig. 8 A), indicating that
MHC/peptide multimers were responsible for the activa-
tion event. In contrast to previous reports in another class I
MHC–restricted system (23), we saw no activation of Ca21
flux by monomeric OVA/Kb (Fig. 8 A). We went further
to test whether we could induce OT-I T cell activation by
Figure 6. Role of CD8 binding of multimeric altered peptide ligands.
OT-I cells were incubated at 48C for 2 h with Kb multimers containing
OVA, SIY, G4, or E1 peptides in the absence of anti-CD8 antibodies (A)
or in the presence of saturating amounts of 53.6.7 (B) or 3.168 (C). In the
case of 3.168, the histograms with all the multimers overlap that of the
negative control SIY/Kb
 multimer. Results are representative of four sep-
arate experiments.
Figure 7. Density plot showing real time analysis of multimer binding
and Ca21 flux response. Indo-1AM–loaded OT-I RAG-12/2 LN cells
were analyzed by FACS® for 1 min, at which time OVA/Kb (left panels)
or SIY/Kb (right panels) PE-conjugated multimers (10 mg/ml) were
added. Analysis of multimer binding (A) and Ca21 mobilization (as re-
flected by changes in the fluorescence of the Indo-1 dye; (B) was deter-
mined for the same population of cells. Analysis of this and two other ex-
periments indicates that 83–91% of OT-I cells mobilized Ca21 in
response to the OVA/Kb multimer.341 Daniels and Jameson
multimerization of the monomeric ligands “on-the-fly” by
addition of SA–PE into the sample and following the re-
sponse for a further 8 min. This approach showed a slight
but noticeable rise in intracellular Ca21 consistent with a
presumably inefficient assembly of OVA/Kb multimers and
subsequent OT-I activation (Fig. 8 A). The inefficiency of
this response is to be expected, as multimerization takes
several hours in our standard protocol, making the weak
Ca21 flux observed even more significant.
Further analysis of activation with multimer complexes
investigated the role of CD8. Again, the OVA/Kb multi-
mer induced a strong, sustained Ca21 flux in OT-I cells
that was not induced by the control (SIY/Kb) multimer
(Fig. 8, B and C). This flux was similar in magnitude and
duration to that induced by cross-linked anti-CD3 anti-
body 500.A2 (Fig. 8 D). To study the role of CD8 in this
process, we pretreated the cells with anti-CD8 antibody,
either 3.168 or 53.6.7. Fluorochrome-labeled anti-CD8
antibodies and multimers were used so that staining of the
responding T cell populations could be studied during the
experiment. Activation of the OT-I cells was unaffected by
prestaining with the 53.6.7 antibody, whereas activation was
completely blocked using 3.168 (Fig. 8, B and C). It was
possible that pretreatment with 3.168 was inducing more
than simple blockade of multimer binding. This was a spe-
cial concern, as anti-CD8–treated cells frequently showed
slight elevations in basal levels of intracellular Ca21 not ob-
served with unstained control populations (Fig. 8). How-
ever, pretreatment of OT-I cells with the “blocking” 3.168
antibody had no effect on the response to anti-CD3 (Fig.
8 D), which argues against a general inhibitory effect of the
anti-CD8 antibody.
Similar experiments were used for 2C cells. We took ad-
vantage of the naturally occurring population of CD82 2C
cells. Anti-CD3 antibody cross-linking was able to induce
Ca21 flux in both populations of CD81 and CD82 2C cells
(data not shown) and, as for OT-I cells, activation of 2C cells
was observed only using the specific multimer (in this case
SIY/Kb; Fig. 8 E). Intriguingly, from preliminary experi-
ments it was evident that multimer induced activation
failed to stimulate all of the 2C cells. To determine if there
Figure 8. Ca21 flux response in OT-I or 2C T cells induced by MHC/
peptide monomers and multimers. (A) Ca21 mobilization in OT-I RAG-
12/2 LN cells treated with OVA/Kb multimers (blue line), free OVA
peptide (red line), or OVA/Kb monomeric complexes (black line). In the
case of the monomers, SA–PE was added at 8 min (arrow) and the sample
reanalyzed for a further z8 min. The OVA/Kb multimer trace is taken
from an 8-min time course and overlaid here as a representation of a re-
sponding population. (B and C) OT-I cells were pretreated with either
3.168 (B) or 53.6.7 (C) antibodies (black lines) before stimulation with
OVA/Kb multimers or were exposed to SIY/Kb multimers (red lines) or
OVA/Kb multimers (blue lines) in the absence of anti-CD8 antibodies.
(D) In parallel, OT-I cells were stimulated by addition of anti-CD3 anti-
body 500.A2 (aCD3 antibody) plus cross-linking goat anti–mouse Ig,
with (black line) or without (blue line) pretreatment with 3.168. 2C cells
were stimulated with SIY/Kb or OVA/Kb multimers in the presence or
absence of anti-CD8 antibodies 53.6.7 (E) or 3.168 (F). Response to the
SIY/Kb multimer in the absence of any CD8 antibodies is shown in both
panels (blue line). In E, the CD81 (red line) and CD82 (black line) popu-
lations are delineated by 53.6.7. Exposure to OVA/Kb multimers in the
presence of 53.6.7 (green line) served as a negative control in this re-
sponse. In F, the CD81 (black line) and CD82 (red line) populations are
delineated by 3.168. All traces indicate the median of the responding
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was a difference in the capacity of CD81 and CD82 popu-
lations to respond to SIY/Kb multimers, we used the 53.6.7
antibody to separate these subsets. The CD82 population
failed to respond to SIY/Kb multimer stimulation, whereas
the CD81 population responded well (Fig. 8 E). In the pres-
ence of 3.168, however, neither the CD82 nor CD81 pop-
ulations responded (Fig. 8 F). Over the entire time course,
there was a slight rise in intracellular Ca21 in the CD82
population (Fig. 8, E and F), and we are investigating the
possibility that the response of CD82 cells is kinetically de-
layed. In any case, the effect of CD8 on T cell activation by
multimeric ligands mirrored the staining profile, with the
important exception that, although CD82 2C cells can bind
well to the SIY/Kb multimer in the staining protocol, they
do not respond efficiently to it by Ca21 flux.
We also studied a later activation parameter, the upregu-
lation of CD69, which was induced after 3 h by agonist
ligands (OVA/Kb in the case of OT-I and SIY/Kb for 2C
cells) but not by noncognate or nonagonistic multimeric
ligands (data not shown). These data are in keeping with
the results of the Ca21 flux experiments and suggest that
stimulation with cognate MHC/peptide multimers is capa-
ble of inducing new gene transcription.
Discussion
The production of synthetic MHC/peptide multimers
has caused a revolution in T cell biology, allowing detec-
tion of antigen-specific T cell populations by using in-
creased avidity to compensate for the very low affinity of
TCRs for MHC/peptide ligands (16, 41). Although there
have been numerous papers published showing the capacity
of multimers to bind antigen-specific TCRs, there has been
comparatively little analysis of the role of the coreceptors in
binding and T cell activation by these multimeric ligands.
A few reports using multimeric class II MHC/peptide
ligands to analyze the minimal requirements for TCR
binding and T cell activation reached the unanimous con-
clusion that the CD4 coreceptor is critical for activation of
proximal signal transduction events but not required at all
for TCR binding to either dimeric or multimeric MHC/
peptide ligands (8–10). Our data using class I MHC/pep-
tide multimers differ from these results in several key ways.
First, we observe that TCR binding to cognate class I multi-
mers is highly CD8 dependent, as shown by blockade with
anti-CD8 antibodies and analysis of CD82 class I–restricted
T cells. The degree of CD8 dependence differed between
the two TCR systems studied, but in both cases the multi-
mer interaction was profoundly influenced by CD8 partici-
pation. Second, in contrast to the data of Boniface et al. (10),
we found that Ca21 flux was efficiently induced by low
doses of class I/peptide multimers. Moreover, the size of
the responding population and uniformly raised levels of
intracellular Ca21 (Fig. 7) suggest that this is a sustained
Ca21 flux response, rather than the transient “partial agonist–
like” response observed by Boniface et al. (10). However,
using the flow cytometric approach it is difficult to deter-
mine the extent of Ca21 oscillations in individual cells, so
accurate resolution of this question will require single-cell
analysis. Our functional assay data also differs from that of
Delon et al. and Abastado et al., who showed that mono-
meric class I MHC/peptide complexes induced sustained
Ca21 flux, provided that CD8 was accessible, whereas dimeric
MHC/peptide complexes could activate even in the ab-
sence of CD8 (23, 24). In contrast, we found that MHC/
peptide monomers fail to activate Ca21 flux and that the
activation induced by multimeric MHC/peptide com-
plexes is still highly CD8 dependent. We also showed that
generation of multimers from monomer ligands during the
time course of the Ca21 flux experiment could induce OT-I
T cell activation, albeit inefficiently. In comparing our re-
sults with those of Delon et al. (23), it is important to note
that they studied primed CTLs, whereas we describe re-
sponses of naive T cells. Differences between the minimal
activation requirements for naive versus effector cells are
under investigation.
The profound effect of CD8 on OVA/Kb multimer bind-
ing to OT-I was initially unexpected, as the current litera-
ture suggests that multimeric MHC/peptide ligands bind
efficiently to the TCR alone and because the affinity of
the OT-I receptor is in the same range as class II MHC–
restricted TCRs, which evidently do not require coreceptor
participation for binding (8–10, 41, 42). We were concerned
that anti-CD8 antibody binding may indirectly influence
accessibility to the TCR, for example through some conse-
quence of T cell activation or by induction of TCR inter-
nalization. This is unlikely given the consistency in results
when parameters such as Ig isotype, temperature, and dura-
tion of staining and the presence or absence of azide were
varied. Furthermore, expression of TCRs as assessed by
CD3 staining was unaffected by exposure to anti-CD8 an-
tibodies (data not shown), arguing against modulation of
the TCR in these experiments. Perhaps most convincing
are the parallel results obtained using the 2C system, in which
multimer staining was not lost after anti-CD8 blockade but
merely reduced to approximately the same level as naturally
occurring CD82 2C cells. Furthermore, the similarity of our
data to that of Luescher et al. (5), who showed CD8 depen-
dence for TCR binding to monomeric MHC/peptide
ligands, suggests that our results are not an artifact of using
multimeric TCR ligands. Instead, we are left with the idea
that the inherent affinity of the OT-I TCR is insufficient
to allow even multimeric ligand binding if CD8 participa-
tion is blocked. Further work will be required to determine
how this obligate role for CD8 for OT-I TCR engagement
by multimers is mediated. An interesting result in this con-
text was the capacity of blocking anti-CD8 antibodies to in-
duce loss of prebound MHC/peptide multimers (Fig. 4).
This suggests that the MHC/peptide–TCR interaction is
dynamic in nature and that “stable” multimer binding re-
flects a series of TCR–ligand release and rebinding, which
is influenced by CD8. In keeping with this, the “enhanc-
ing” antibody 53.6.72 appeared to stabilize prebound MHC/
peptide multimer (Fig. 4), raising the possibility that bind-
ing by this antibody lengthens the half-life of the MHC/
peptide–TCR (–CD8) interaction. Thus, we show that cu-343 Daniels and Jameson
mulative multimer binding is enhanced by CD8 but can be
reversed by sustained blockade of certain CD8 combining
sites. On the other hand, recent measurements of cell sur-
face–associated 2C TCR binding to the SIY/Kb complex
indicate that the affinity of this interaction is extremely high
(43). Thus, the interaction of this TCR with the SIY/Kb
ligand may inherently be less coreceptor dependent.
We also demonstrated that CD8 played a critical role in
OT-I TCR binding to multimers containing low-affinity,
altered peptide ligands. In keeping with the predictions of
Crawford et al. (9), we saw a ranking of multimer binding
consistent with multimer affinity for the OT-I TCR. How-
ever, in our case this was again strongly influenced by ma-
nipulation of the coreceptor. Most striking is the effect of
anti-CD8 on binding to the E1/Kb, which we previously
showed was a low-affinity TCR antagonist (26, 39, 40). Bind-
ing to this multimeric ligand is detectable but weak on nor-
mal OT-I cells but is strongly enhanced by the 53.6 anti-
body, whereas it is completely blocked by the other anti-CD8
antibodies tested. Interestingly, previous work had indi-
cated that high levels of CD8 expression could convert this
ligand into a weak agonist (40). Our data is in contrast, how-
ever, with the conclusion made by Madrenas et al. and
Hampl et al., who proposed that the CD4 coreceptor plays
no role in binding to TCR antagonists (11, 12). Aside from
potential differences between the roles of CD4 and CD8 in
antagonist recognition, it is interesting to note that there
are also large differences in the ratio of TCR affinity for ag-
onists versus antagonists in these systems. Thus, TCR an-
tagonists bind with only three- to fivefold lower affinity
than agonists in the OT-I system (39), but the difference in
the 2B4 system used by Lyons et al. was 10–50-fold (44).
Thus, differences in the involvement of the coreceptor in
encounter with antagonists may relate to the core TCR af-
finity for these ligands. This raises the concern, however,
that coreceptor participation in antagonist recognition may
vary depending on the affinity of the particular TCR and
hence may not be generalizable.
We conclude that TCR interactions and activation by
multimeric MHC/peptide ligands on the surfaces of living
CD81 cells typically involve CD8. These conclusions are
similar to those presented by Luescher et al. (5) using a Kd-
restricted T hybridoma system in which TCR binding to
MHC/peptide monomers could be detected. Thus, data from
three different TCR systems involving two MHC class I
alleles were strikingly similar and imply that this role of
CD8 for TCR–MHC/peptide interactions can be general-
ized, at least in the mouse system. An intriguing outcome
of these studies was the diverse effect of different antibodies
to CD8. The CD8a antibody 53.6.7 enhanced TCR asso-
ciation by cognate (but not noncognate) MHC/peptide
ligands, whereas the CD8a antibodies CT-CD8a and 3.168
and the CD8b antibody 53.5.8 all dramatically blocked TCR
binding and, correspondingly, T cell activation. It is not
clear why some CD8 antibodies augment TCR–MHC/
peptide binding and others block it. Presumably, 53.6.7 fa-
vors encounter between CD8 and the TCR or CD8 and
class I, whereas the other antibodies block these interac-
tions. Incidentally, our results explain why the role of CD8
in multimer binding had not been appreciated until this re-
port: previous studies in the mouse exclusively used the
53.6.7 antibody to stain for CD8a (17–19), which would
be expected to augment rather than block multimer bind-
ing. It is also of interest that the CD8b antibody tested
shows efficient blockade of multimer binding. CD8b ex-
pression is known to enhance T cell responses (45, 46) and
development (47–49), but it is unclear whether this chain
plays a direct role in MHC class I binding or T cell signal-
ing (2, 3, 50). Interestingly, 53.5.8 does not appear to oc-
clude the CD8a chain, as determined by antibody binding
competition (51), and has only a mild effect on CD8 bind-
ing to immobilized class I molecules (5), implying a mini-
mal role in CD8-mediated adhesion. Thus, it is tempting to
speculate that CD8b blockade may affect the TCR–CD8
rather than the CD8–MHC interaction. Such a role for
CD8b is supported by experiments indicating that CD8b is
more efficient than CD8a at association with the TCR
(52). Also in support of our observations is a report describ-
ing partial blockade by 53.5.8 of multimer binding to poly-
clonal antigen–specific T cells (53).
The results observed in the 2C system deserve special at-
tention. Although SIY/Kb binding was clearly not entirely
dependent on CD8, overt activation of these cells by mul-
timer ligands did require CD8. This matches well with re-
ports that anti-CD8–treated 2C cells and/or CD82 2C cells
fail to respond to physiological densities of MHC/peptide
antigen expressed on APCs (35), although this CD8 re-
quirement could be overcome by very high antigen density
(36). Thus, our multimeric system appears to mirror the re-
sponse of 2C to physiological levels of antigen expressed by
APCs. Interestingly, our data also correlate with findings of
Garcia et al. (33), who used surface plasmon resonance to
show a role for CD8 in enhancing TCR–MHC/peptide
interactions, including the 2C receptor. These data were
reinterpreted by Wyer et al. (13), who suggested that CD8
multimers contributed to the evident enhancement of TCR
binding observed by Garcia et al. As we deliberately used
multimeric MHC/peptide ligands in this work, it may not
be surprising that we observed a similar enhancing role for
CD8 in our system.
Lastly, a technical consequence of our studies is that the
use of CD8 antibodies in flow cytometric analysis can dras-
tically influence TCR binding to MHC/peptide ligands.
Moreover, our data using low-affinity TCR ligands to-
gether with the enhancing anti-CD8 antibody 53.6.7 indi-
cates that significant multimer staining may be seen using
ligands that fail to induce a functional response. It is not
clear what influence the commonly used anti–human CD8
antibodies will exert, but the effects documented here raise
a cautionary note.
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